Compositions for increasing half-life of a therapeutic agent in felines and methods of use
Provided are compositions for increasing the half-life of a polypeptide or polypeptides in a feline and methods of their use. The compositions involve variant feline IgG Fc regions.
1. A polypeptide comprising a feline IgG Fc region variant, wherein the polypeptide comprises an amino acid substitution at at least one position selected from the group consisting of:
(i) a position that corresponds to amino acid position 286 of a wild type feline IgG, wherein the amino acid substitution is T286E;
(ii) a position that corresponds to amino acid position 311 of a wild type feline IgG, wherein the amino acid substitution is Q311V; and
(iii) a position that corresponds to amino acid position 428 of a wild type feline IgG, wherein the amino acid substitution is S428Y;
wherein the amino acid positions are based on EU numbering, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 3, wherein the polypeptide has increased binding affinity to feline FcRn when compared to an Fc domain of the wild type feline IgG, and wherein the polypeptide binds to feline FcRn at a higher level at pH 6.0 than at pH 7.4.
2. The polypeptide of claim 1 , wherein the wild type feline IgG is a feline IgG1a comprising an Fc domain having an amino acid sequence of SEQ ID NO: 1.
3. The polypeptide of claim 1 , wherein the wild type feline IgG is a feline IgG1b comprising an Fc domain having an amino acid sequence of SEQ ID NO: 2.
4. The polypeptide of claim 1 , wherein the wild type feline IgG is a feline IgG2 comprising an Fc domain having an amino acid sequence of SEQ ID NO: 3.
5. The polypeptide of claim 1 , further comprising a polypeptide protcin selected from the group consisting of EPO, CTLA4, LFA3, VEGFR1/VEGFR3, IL-IR, IL-4R, GLP-1 receptor agonist, and Thrombopoietin binding peptide.
6. A pharmaceutical composition comprising (i) the polypeptide of claim 1 , and (ii) a pharmaceutically acceptable excipient.
7. A nucleic acid or nucleic acids encoding the polypeptide of claim 1 .
8. An expression vector or expression vectors comprising the nucleic acid or nucleic acids of claim 7 .
9. A host cell comprising the nucleic acid or nucleic acids of claim 7 or an expression vector or expression vectors comprising the nucleic acid or nucleic acids.
10. A method of making a polypeptide, the method comprising:
(a) providing a nucleic acid or nucleic acids of claim 7 ;
(b) expressing the nucleic acid or nucleic acids in a host cell culture, thereby producing the polypeptide; and
(c) collecting the polypeptide produced in (b) from the host cell culture.
11. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid substitution at a position that corresponds to amino acid position 311 of a wild type feline IgG, wherein the amino acid substitution is Q311V.
12. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid substitution at a position that corresponds to amino acid position 428 of a wild type feline IgG, wherein the amino acid substitution is S428Y.
13. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid substitution at a position that corresponds to amino acid position 286 of a wild type feline IgG, wherein the amino acid substitution is T286E.
14. The polypeptide of claim 1 , further comprising a binding domain, wherein the binding domain comprises a ligand binding domain of a feline receptor protein.
15. The polypeptide of claim 1 , further comprising a binding domain, wherein the binding domain comprises a nanobody.
16. The polypeptide of claim 1 , further comprising a binding domain, wherein the binding domain comprises an extracellular domain of a feline receptor protein.
17. A polypeptide comprising a feline IgG Fc region variant, wherein the polypeptide comprises two or more amino acid substitutions, wherein the two or more amino acid substitutions are selected from the group consisting of:
(i) an amino acid substitution at a position that corresponds to amino acid position 286 of a wild type feline IgG, wherein the amino acid substitution is T286E;
(ii) an amino acid substitution at a position that corresponds to amino acid position 311 of a wild type feline IgG, wherein the amino acid substitution is Q311V;
(iii) an amino acid substitution at a position that corresponds to amino acid position 428 of a wild type feline IgG, wherein the amino acid substitution is S428Y;
wherein the amino acid positions are based on EU numbering, wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 3, wherein the two or more amino acid substitutions are at different positions, wherein the polypeptide has increased binding affinity to feline FcRn when compared to (a) an Fc domain of the wild type feline IgG, and (b) a polypeptide comprising only one of the two or more amino acid substitutions, and wherein the polypeptide binds to feline FcRn at a higher level at pH 6.0 than at pH 7.4.
18. The polypeptide of claim 17 , wherein the two or more amino acid substitutions comprise an amino acid substitution at a position that corresponds to amino acid position 286 of a wild type feline IgG, wherein the amino acid substitution is T286E.
19. The polypeptide of claim 17 , wherein the two or more amino acid substitutions comprise an amino acid substitution at a position that corresponds to amino acid position 311 of a wild type feline IgG, wherein the amino acid substitution is Q311V.
20. The polypeptide of claim 17 , wherein the two or more amino acid substitutions comprise an amino acid substitution at a position that corresponds to amino acid position 428 of a wild type feline IgG, wherein the amino acid substitution is S428Y.
21. The polypeptide of claim 17 , wherein the polypeptide comprises:
(i) an amino acid substitution at a position that corresponds to amino acid position 286 of a wild type feline IgG, wherein the amino acid substitution is T286E;
(ii) an amino acid substitution at a position that corresponds to amino acid position 311 of a wild type feline IgG, wherein the amino acid substitution is Q311V; and
(iii) an amino acid substitution at a position that corresponds to amino acid position 428 of a wild type feline IgG, wherein the amino acid substitution is S428Y.